NCT03776630Active, not recruiting
Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors
Source: ClinicalTrials.gov · Last updated 12 Aug 2025
Brief summary (registry, in English)
This trial is a non-randomized, open label and multicenter study. It aims to : for endometrial cancer.:validate the 5-miR index assessed in plasma samples as a diagnostic marker to assess the risk of lymph node metastases for ovarian cancer : to validate the previous finding on the prognostic value of the pre-/post-treatment variation of miR200b plasma concentrations with regards to PFS (the investigators mean the primary treatment including up-front or post-chemotherapy debulking and adjuvant chemotherapy).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 363 (actual)
- First submitted
- 24 Sept 2018
- Start date
- 23 May 2019
- Primary completion date
- 18 May 2024
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT03776630
What you commit to
- Study type: Interventional
- Participants enrolled: 363
- From 23 May 2019 to the primary completion date, 18 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Ongoing pregnancy;
- Control patients:
- \- Previous history of cancer.
- EC patients
- Previous history of cancer. OC patients
- Non epithelial cancer.
- Previous history of cancer - except for patients who developed breast cancer at least 5 years or more before ovarian cancer.
Other
- For all patients (OC, EC, Control)
- Unable or unwilling to comply with the protocol requirements and/or unwilling to sign an informed consent form.
- Deprived of liberty or under legal protection measure;
- FIGO stage IV at preoperative imaging techniques.
Who the study is looking for
- For all patients (EC, OC, Control)
- Written informed consent;
- Age ≥ 18 years old;
- Patient affiliated to social security.
- EC patients
- Histologically proven EC ;
- Type 1 and 2 EC;
- FIGO stage I or II or III EC requiring first intention surgical staging.
- OC patients
- Histologically proven OC or strong suspicion of OC on clinical arguments (abdomino-pelvian mass detected by palpation or echography and/or ascitis and/or elevated CA125);
- Epithelial OC: any histological subtype;
- FIGO stage I to IV OC.
- Control patients - Any lesion which is supposed to be benign and requires surgery. -
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de chirurgie et oncologie gynécologique et mammaire Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.